CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | 7,12-dimethyltetraphene |
|
Accession: | CHEBI:254496
|
browse the term
|
Definition: | A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke. |
Synonyms: | related_synonym: | 1,4-Dimethyl-2,3-benzphenanthrene; 6,7-Dimethyl-1,2-benzanthracene; 7,12-DMBA; 7,12-Dimethyl-1,2-benzanthracene; 7,12-Dimethyl-1:2-benz(a)anthracene; 7,12-Dimethylbenz(a)anthracene; 7,12-Dimethylbenzanthracene; 7,12-Dimethylbenzanthrancene; 7,12-dimethylbenzo[a]anthracene; 9,10-Dimethyl-1,2-benzanthracene; 9,10-Dimethyl-1,2-benzanthrazen; 9,10-Dimethylbenz(a)anthracene; DMBA; Formula=C20H16; InChI=1S/C20H16/c1-13-16-8-5-6-9-17(16)14(2)20-18(13)12-11-15-7-3-4-10-19(15)20/h3-12H,1-2H3; InChIKey=ARSRBNBHOADGJU-UHFFFAOYSA-N; SMILES=Cc1c2ccccc2c(C)c2c1ccc1ccccc21 |
| alt_id: | CHEBI:59032 |
| xref: | Beilstein:1912135; CAS:57-97-6; Gmelin:263937; KEGG:C19488; LINCS:LSM-37159 |
| xref_mesh: | MESH:D015127 |
| xref: | PMID:11488430; PMID:12839762; PMID:16020197; PMID:18992763; PMID:7561049 |
|
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ABCB1B mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
affects response to substance |
ISO |
ABCC6 gene SNP affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:25622337 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ABHD3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr18:1,723,203...1,778,488
Ensembl chr18:1,720,718...1,803,428
|
|
G |
Acad8 |
acyl-CoA dehydrogenase family, member 8 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ACAD8 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 8:25,382,271...25,406,404
Ensembl chr 8:25,382,273...25,406,414
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ACAT1 protein |
CTD |
PMID:38307155 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Actb |
actin, beta |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of ACTB mRNA |
CTD |
PMID:21785161 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ACTG2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of ACTN1 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of ACTN1 protein |
CTD |
PMID:22248470 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Actn3 |
actinin alpha 3 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ACTN3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:202,159,081...202,175,012
Ensembl chr 1:202,159,082...202,175,012
|
|
G |
Actn4 |
actinin alpha 4 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ACTN4 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847
|
|
G |
Actr3b |
actin related protein 3B |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ACTR3B mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:9,261,631...9,355,496
Ensembl chr 4:9,262,233...9,355,441
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ADAMTS9 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adcy5 |
adenylate cyclase 5 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ADCY5 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adgrl4 |
adhesion G protein-coupled receptor L4 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ADGRL4 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:240,354,909...240,457,231
Ensembl chr 2:240,354,941...240,457,225
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ADH7 mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of ADH7 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Adm |
adrenomedullin |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ADM mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Aen |
apoptosis enhancing nuclease |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of AEN mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] |
CTD |
PMID:24792773 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Agxt |
alanine--glyoxylate aminotransferase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of AGXT protein |
CTD |
PMID:38307155 |
|
NCBI chr 9:93,675,384...93,685,337
Ensembl chr 9:93,675,384...93,685,336
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of AHCYL1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity decreases expression multiple interactions affects localization affects binding increases expression affects response to substance |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of AHR mRNA 9,10-Dimethyl-1,2-benzanthracene promotes the reaction [AHR protein results in increased expression of CCL5 mRNA]; AHR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DAZL mRNA]; AHR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DDX4 mRNA]; AHR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PRDM1 mRNA]; biochanin A inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene promotes the reaction [AHR protein binds to CYP1A1 promoter]]; Eugenol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the localization of AHR protein] 9,10-Dimethyl-1,2-benzanthracene binds to and results in increased activity of AHR protein; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in decreased expression of CXCL10 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of ADH7 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of AHRR mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of ALDH3A1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of ARL6IP5 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of BTG2 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CCL2 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CCNG1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CCNO mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CENPB mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CXCL5 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of DDIT4 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of DOK1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of FOSL1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of GCHFR mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of GPRC5A mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of IER3 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of INHBB mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of LPL mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of NFE2L2 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of NQO1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PGD mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PHLDA1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PHLDA3 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PTGS2 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PTX3 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of SPP1 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of SULF2 mRNA; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of TIPARP mRNA; [AHR mRNA affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which results in decreased expression of CYP1A1; AHR mRNA promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of ARTN protein]; AHR mRNA promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL4RA]; AHR mRNA promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TSLP]; galangin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the localization of AHR protein] 9,10-Dimethyl-1,2-benzanthracene binds to AHR protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of AHR mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of AHR protein AHR affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene; AHR mRNA affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene binds to and results in increased activity of AHR protein; AHR protein promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDH13 mRNA]; betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AHR protein] |
CTD |
PMID:3024361 PMID:9855628 PMID:10953044 PMID:12117779 PMID:12200463 PMID:12559965 PMID:14678569 PMID:15667830 PMID:16903077 PMID:17275817 PMID:18205319 PMID:20562217 PMID:22406437 PMID:25110319 PMID:27869817 PMID:32553695 PMID:33759307 PMID:38307155 More...
|
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of AHRR mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of AHRR mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of AHRR mRNA |
CTD |
PMID:27891153 PMID:32553695 |
|
NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of AKR1B10 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
AKR7A2 protein results in increased reduction of and affects the activity of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:21910479 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression increases phosphorylation |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of AKT1 protein modified form 9,10-Dimethyl-1,2-benzanthracene results in increased expression of AKT1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased phosphorylation of AKT1 protein |
CTD |
PMID:21785161 PMID:24576726 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ALAS2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ALB protein |
CTD |
PMID:38307155 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ALDH3A1 mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ALDOA protein |
CTD |
PMID:22248470 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ANAPC5 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions increases methylation |
EXP |
[9,10-Dimethyl-1,2-benzanthracene results in increased methylation of ANGPTL4 promoter] which results in decreased expression of ANGPTL4 mRNA |
CTD |
PMID:21489049 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ANK mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:78,153,027...78,280,181
Ensembl chr 2:78,153,026...78,280,187
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of ANXA1 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of ANXA1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of ANXA1 protein |
CTD |
PMID:12376462 PMID:22248470 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of ANXA2 protein |
CTD |
PMID:22248470 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa8 |
annexin A8 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ANXA8 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions decreases expression |
ISO |
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein |
CTD |
PMID:25478867 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions increases expression |
ISO |
Metformin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of APEX1 mRNA] |
CTD |
PMID:25697376 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apobec1 |
apolipoprotein B mRNA editing enzyme catalytic subunit 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of APOBEC1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:155,800,030...155,828,515
Ensembl chr 4:155,800,887...155,827,390
|
|
G |
Apoc1 |
apolipoprotein C1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of APOC1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Apoe |
apolipoprotein E |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of APOE mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of AQP1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of AQP3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp5 |
aquaporin 5 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of AQP5 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Ar |
androgen receptor |
multiple interactions increases activity |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene binds to and results in decreased activity of AR protein; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Metribolone results in increased activity of AR protein] 9,10-Dimethyl-1,2-benzanthracene results in increased activity of AR protein |
CTD |
PMID:10771140 PMID:18324785 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ARHGAP11A mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559
|
|
G |
Arhgap6 |
Rho GTPase activating protein 6 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ARHGAP6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr X:24,953,464...25,490,003
Ensembl chr X:24,953,464...25,488,663
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arl16 |
ARF like GTPase 16 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of ARL16 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr10:105,737,455...105,739,631
Ensembl chr10:105,737,154...105,739,824
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of ARL6IP5 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ARL6IP5 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ARNT protein betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of ARNT protein] |
CTD |
PMID:33759307 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ARRDC3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Artn |
artemin |
multiple interactions increases expression |
ISO |
AHR mRNA promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of ARTN protein] |
CTD |
PMID:27869817 |
|
NCBI chr 5:131,458,596...131,470,193
Ensembl chr 5:131,464,756...131,468,025
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of ASAH1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Asip |
agouti signaling protein |
multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the reaction [A gene mutant form results in decreased expression of GJA4 protein]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [A gene mutant form results in decreased expression of ATM mRNA]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [A gene mutant form results in decreased expression of BRCA1 protein]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [A gene mutant form results in decreased expression of PRKDC mRNA]; 9,10-Dimethyl-1,2-benzanthracene promotes the reaction [A gene mutant form results in increased expression of PARP1 mRNA]; 9,10-Dimethyl-1,2-benzanthracene promotes the reaction [A gene mutant form results in increased expression of PARP1 protein]; [A gene mutant form co-treated with 9,10-Dimethyl-1,2-benzanthracene] affects the expression of GJA4 protein; A gene mutant form affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 mRNA]; A gene mutant form affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of H2AX protein]; A gene mutant form affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 protein]; A gene mutant form inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BRCA1 protein]; A gene mutant form inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 mRNA]; A gene mutant form inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of XRCC6 protein] |
CTD |
PMID:25447408 PMID:25448685 |
|
NCBI chr 3:143,473,584...143,561,170
Ensembl chr 3:143,555,696...143,561,171
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ASS1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ATAD2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atg10 |
autophagy related 10 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ATG10 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression decreases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased phosphorylation of ATM protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of ATM protein 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ATM mRNA 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [A gene mutant form results in decreased expression of ATM mRNA] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of ATM mRNA |
CTD |
PMID:23969067 PMID:25448685 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ATP5F1A protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of ATP5F1A protein |
CTD |
PMID:22248470 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of ATP5F1B protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of ATP5F1B protein |
CTD |
PMID:22248470 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Atp5if1 |
ATP synthase inhibitory factor subunit 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ATP5IF1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 5:144,738,950...144,742,668
Ensembl chr 5:144,738,950...144,742,668
|
|
G |
Atp6ap2 |
ATPase H+ transporting accessory protein 2 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of ATP6AP2 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr X:10,183,983...10,210,948
Ensembl chr X:10,183,068...10,210,918
|
|
G |
Atrnl1 |
attractin like 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ATRNL1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:256,670,976...257,219,291
Ensembl chr 1:256,670,627...257,213,197
|
|
G |
Axin1 |
axin 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of AXIN1 mRNA |
CTD |
PMID:36863560 |
|
NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of BASP1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 2:75,816,130...75,863,801
Ensembl chr 2:75,816,122...75,864,043
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of BAX mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BAX mRNA [Ruthenium binds to Phloretin] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of BAX protein; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in decreased expression of BAX protein; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of BAX protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; geraniol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in decreased expression of BAX protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein] alpha-naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of BAX mRNA] |
CTD |
PMID:20562217 PMID:22760862 PMID:24269759 PMID:25478867 PMID:30101532 PMID:32662567 PMID:33347706 PMID:34896434 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of BBC3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bbs9 |
Bardet-Biedl syndrome 9 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of BBS9 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 8:21,013,865...21,437,934
Ensembl chr 8:21,013,944...21,437,930
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of BCL2 mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of BCL2 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of BCL2 protein; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Plant Extracts co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of BCL2 protein; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of BCL2 protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Eugenol inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of BCL2 mRNA]; Eugenol inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of BCL2 protein]; geraniol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of BCL2 protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein] [Ruthenium binds to Phloretin] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Ghee inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein |
CTD |
PMID:20103723 PMID:20537511 PMID:21088903 PMID:22760862 PMID:25478867 PMID:30101532 PMID:32662567 PMID:33347706 PMID:34896434 More...
|
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl6 |
BCL6, transcription repressor |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of BCL6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of BDNF mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of BECN1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BECN1 protein |
CTD |
PMID:24576726 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] |
CTD |
PMID:24792773 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Brat1 |
BRCA1-associated ATM activator 1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of BRAT1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr12:13,928,889...13,951,760
Ensembl chr12:13,928,898...13,941,248
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
affects response to substance increases expression multiple interactions |
ISO EXP |
BRCA1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BRCA1 protein 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [A gene mutant form results in decreased expression of BRCA1 protein]; A gene mutant form inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BRCA1 protein] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BRCA1 mRNA |
CTD |
PMID:21507987 PMID:23969067 PMID:25448685 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of BTG2 mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of BTG2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
C1qb |
complement C1q B chain |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of C1QB mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C1qc |
complement C1q C chain |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of C1QC mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C1s |
complement C1s |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of C1S mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
|
|
G |
C3 |
complement C3 |
increases expression decreases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of C3 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of C3 protein |
CTD |
PMID:19480007 PMID:38307155 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CALR mRNA |
CTD |
PMID:21785161 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Capza2 |
capping actin protein of muscle Z-line subunit alpha 2 |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of CAPZA2 protein |
CTD |
PMID:22248470 |
|
NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864
|
|
G |
Car2 |
carbonic anhydrase 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CAR2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CAR3 protein |
CTD |
PMID:20045496 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
increases expression decreases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CASK mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CASK mRNA |
CTD |
PMID:12376462 PMID:32553695 |
|
NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694
|
|
G |
Casp2 |
caspase 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CASP2 protein |
CTD |
PMID:21785161 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases expression decreases activity increases expression |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased cleavage of and results in increased activity of CASP3 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CASP3 protein; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; alpha-naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased cleavage of CASP3 protein]; amarogentin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased cleavage of and results in increased activity of CASP3 protein]; aspartyl-glutamyl-valyl-aspartal inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased cleavage of CASP3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased cleavage of CASP3 protein]; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CASP3 protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; CYP1B1 protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased cleavage of CASP3 protein]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; pifithrin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased cleavage of and results in increased activity of CASP3 protein]; pyrene inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased cleavage of CASP3 protein] Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CASP3 protein |
CTD |
PMID:16517061 PMID:21785161 PMID:23969067 PMID:25478867 PMID:30101532 PMID:32662567 PMID:33347706 PMID:35908932 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases activity decreases expression multiple interactions |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein] [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CASP9 protein; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CASP9 protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein] |
CTD |
PMID:25478867 PMID:30101532 PMID:32662567 PMID:33347706 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases activity decreases expression decreases activity |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with argemone oil]] results in decreased activity of CAT protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of CAT protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased activity of CAT protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with argemone oil] results in decreased activity of CAT protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of CAT protein; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased activity of CAT protein]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CAT protein]; geraniol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CAT protein] 9,10-Dimethyl-1,2-benzanthracene results in increased activity of CAT protein 9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein [Ruthenium binds to Phloretin] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CAT protein]; allyl isothiocyanate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein]; betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein]; brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein]; Vitamin K inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein]; zingerone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein] |
CTD |
PMID:20691676 PMID:23033690 PMID:24995432 PMID:25744308 PMID:30027798 PMID:31476248 PMID:32623939 PMID:32662567 PMID:33063951 PMID:33347706 PMID:33759307 PMID:34896434 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbln2 |
cerebellin 2 precursor |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CBLN2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr18:79,940,412...79,948,766
Ensembl chr18:79,942,590...79,947,855
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CCL2 mRNA 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] |
CTD |
PMID:32553695 PMID:36416909 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
citronellol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCL3 mRNA] |
CTD |
PMID:31926054 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene promotes the reaction [AHR protein results in increased expression of CCL5 mRNA] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCL5 mRNA |
CTD |
PMID:12200463 PMID:19480007 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CCL6 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCN2 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CCN2 mRNA |
CTD |
PMID:19480007 PMID:32553695 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn3 |
cellular communication network factor 3 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCN3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCNB1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression increases expression multiple interactions |
ISO IEP EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCND1 mRNA DMBA increases expression of Ccnd1 mRNA and protein in rat mammary gland [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CCND1 mRNA; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CCND1 mRNA] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCND1 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCND1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CCND1 protein |
CTD RGD |
PMID:12097258 PMID:12376462 PMID:21785161 PMID:29663660 PMID:32662567 PMID:12376462 More...
|
RGD:2292404 |
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CCNG1 mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CCNG1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccno |
cyclin O |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CCNO mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CCNO mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:44,630,873...44,633,912
Ensembl chr 2:44,626,369...44,633,914
|
|
G |
Cd109 |
CD109 molecule |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CD109 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 8:79,454,480...79,569,195
Ensembl chr 8:79,454,480...79,569,194
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CD14 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd3d |
CD3 delta subunit of T-cell receptor complex |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CD3D mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 8:45,287,803...45,293,342
Ensembl chr 8:45,288,749...45,301,809
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CD3G mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CD44 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd5 |
Cd5 molecule |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CD5 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
|
|
G |
Cd52 |
CD52 molecule |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CD52 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G |
Cd59b |
CD59b molecule |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of and results in decreased activity of PIGA protein] which affects the localization of CD59 protein; [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of PIGA gene] which results in decreased expression of CD59 protein |
CTD |
PMID:19965957 PMID:20202993 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cd6 |
Cd6 molecule |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CD6 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634
|
|
G |
Cd74 |
CD74 molecule |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of CD74 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CD80 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd81 |
Cd81 molecule |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of CD81 protein |
CTD |
PMID:38307155 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cd93 |
CD93 molecule |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CD93 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDH1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDH1 protein |
CTD |
PMID:29663660 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh13 |
cadherin 13 |
multiple interactions decreases expression |
EXP |
AHR protein promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDH13 mRNA]; alpha-naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDH13 mRNA] |
CTD |
PMID:12559965 PMID:19480007 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDK4 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkal1 |
CDK5 regulatory subunit associated protein 1-like 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CDKAL1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr17:34,718,701...35,271,276
Ensembl chr17:34,718,687...35,407,524
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; [epigallocatechin gallate co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA]; [Plant Extracts co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA]; [Resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA]; [theaflavin co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Eugenol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; theaflavin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA] 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CDKN1A mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A protein |
CTD |
PMID:20043298 PMID:20103723 PMID:21527772 PMID:21785161 PMID:23717041 PMID:25478867 PMID:32553695 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases response to substance multiple interactions increases methylation decreases expression |
ISO |
CDKN2A gene polymorphism results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein |
CTD |
PMID:11544531 PMID:24792773 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN2B mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CEACAM5 protein zingerone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CEACAM5 protein] |
CTD |
PMID:31476248 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Celf5 |
CUGBP, Elav-like family member 5 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CELF5 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322
|
|
G |
Cenpb |
centromere protein B |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CENPB mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:118,396,987...118,399,780
Ensembl chr 3:118,388,546...118,400,470
|
|
G |
Cep112 |
centrosomal protein 112 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CEP112 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:93,366,059...93,833,133
Ensembl chr10:93,366,136...93,833,131
|
|
G |
Cercam |
cerebral endothelial cell adhesion molecule |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CERCAM mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956
|
|
G |
Cfd |
complement factor D |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CFD mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CGREF1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chchd6 |
coiled-coil-helix-coiled-coil-helix domain containing 6 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CHCHD6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:121,803,501...122,024,209
Ensembl chr 4:121,792,717...122,024,216
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CHEK1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of CHI3L1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CIDEC mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Cisd1 |
CDGSH iron sulfur domain 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CISD1 protein |
CTD |
PMID:38307155 |
|
NCBI chr20:17,255,302...17,268,688
Ensembl chr20:17,255,151...17,284,924
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CKAP2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CLCA1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Cldn3 |
claudin 3 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CLDN3 mRNA |
CTD |
PMID:12097258 |
|
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CLEC10A mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435
|
|
G |
Clstn3 |
calsyntenin 3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cnn3 |
calponin 3 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CNN3 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 2:209,518,948...209,550,107
Ensembl chr 2:209,518,948...209,550,104
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of COL1A2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of COL4A6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of COL5A1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a3 |
collagen type V alpha 3 chain |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of COL5A3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853
|
|
G |
Colec10 |
collectin subfamily member 10 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of COLEC10 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:85,744,895...85,806,368
Ensembl chr 7:85,744,895...85,805,675
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of COMT mRNA |
CTD |
PMID:38307155 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Coro1a |
coronin 1A |
increases methylation multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CORO1A promoter [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CORO1A promoter] which results in decreased expression of CORO1A mRNA |
CTD |
PMID:21489049 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Cox6c |
cytochrome c oxidase subunit 6C |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of COX6C protein |
CTD |
PMID:38307155 |
|
NCBI chr 7:67,129,265...67,142,001
Ensembl chr 7:67,111,024...67,141,963
|
|
G |
Cpa6 |
carboxypeptidase A6 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CPA6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 5:8,526,708...8,888,492
Ensembl chr 5:8,526,741...8,888,485
|
|
G |
Cpb1 |
carboxypeptidase B1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CPB1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:102,755,241...102,785,628
Ensembl chr 2:102,755,241...102,785,628
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CPOX mRNA |
CTD |
PMID:32553695 |
|
NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of CREB3L3 mRNA |
CTD |
PMID:27891153 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein]]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein]] |
CTD |
PMID:37352108 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csde1 |
cold shock domain containing E1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of CSDE1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 2:190,546,015...190,582,787
Ensembl chr 2:190,554,980...190,582,784
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Fluoxetine] affects the expression of CSF1R protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride co-treated with Fluoxetine] affects the expression of CSF1R protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride] affects the expression of CSF1R protein |
CTD |
PMID:31332895 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression multiple interactions |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CSF2 mRNA Vitamin K inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CSF2 mRNA] |
CTD |
PMID:14678569 PMID:33063951 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CSF3 mRNA |
CTD |
PMID:14678569 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Csn1s1 |
casein alpha s1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CSN1S1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr14:20,343,620...20,359,614
Ensembl chr14:20,343,619...20,359,614
|
|
G |
Csn2 |
casein beta |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CSN2 protein |
CTD |
PMID:22248470 |
|
NCBI chr14:20,322,581...20,329,818
Ensembl chr14:20,322,581...20,329,817
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CTH mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CTNNB1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CTNNB1 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and affects the localization of CTNNB1 protein; mithramycin A inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of and affects the localization of CTNNB1 protein]; SP1 protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CTNNB1 protein] |
CTD |
PMID:29663660 PMID:36863560 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CTSD mRNA |
CTD |
PMID:12097258 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsw |
cathepsin W |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of CTSW mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:202,772,395...202,777,021
Ensembl chr 1:202,772,572...202,775,964
|
|
G |
Cubn |
cubilin |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CUBN mRNA |
CTD |
PMID:32553695 |
|
NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in decreased expression of CXCL10 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of CXCL10 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CXCL10 mRNA |
CTD |
PMID:27891153 PMID:32553695 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of CXCL13 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of CXCL1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CXCL5 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CXCL5 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cxcr6 |
C-X-C motif chemokine receptor 6 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CXCR6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 8:123,434,417...123,439,568
Ensembl chr 8:123,416,325...123,439,526
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions increases expression |
EXP |
tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYB5A protein]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYB5A protein] |
CTD |
PMID:24995432 PMID:27091720 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of CYB5R3 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases response to substance increases metabolic processing increases expression multiple interactions affects response to substance increases activity |
ISO EXP |
CYP1A1 protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 mRNA]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of CYP1A1 protein; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 mRNA; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein; betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; Estradiol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; Resveratrol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein] CYP1A1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CYP1A1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein 2'-hydroxychalcone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1A1 protein]; 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; 3-(3-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1A1 protein]; 3-(3-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; 5-androstene-16-fluoro-17-one inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; 7-ketocholesterol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of CYP1A1 protein; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene; [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] which results in increased expression of TP53 protein modified form; [Tetrachlorodibenzodioxin promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]] which results in increased chemical synthesis of 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol; biochanin A inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene promotes the reaction [AHR protein binds to CYP1A1 promoter]]; biochanin A inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1A1 protein]; biochanin A inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; CYP1A1 protein results in increased metabolism of and results in increased activity of 9,10-Dimethyl-1,2-benzanthracene; Dehydroepiandrosterone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1A1 protein]; Dehydroepiandrosterone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; Eugenol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; Eugenol inhibits the reaction [CYP1A1 protein results in increased metabolism of and results in increased activity of 9,10-Dimethyl-1,2-benzanthracene]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; Metformin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of CYP1A1 protein]; Metformin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; Resveratrol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; S-sulindac inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1A1 protein]; S-sulindac inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA] 1-(1-propynyl)pyrene inhibits the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of CYP1A1 protein; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; [[benzo(c)phenanthrene results in increased expression of CYP1A1 protein] promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]] which results in increased chemical synthesis of 9,10-Dimethyl-1,2-benzanthracene analog; [AHR mRNA affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which results in decreased expression of CYP1A1; [benzo(c)phenanthrene promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]] which results in increased chemical synthesis of 9,10-Dimethyl-1,2-benzanthracene analog; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of CYP1A1 mRNA; [Tetrachlorodibenzodioxin promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]] which results in increased chemical synthesis of 9,10-Dimethyl-1,2-benzanthracene analog; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] |
CTD |
PMID:7756127 PMID:8674863 PMID:8961944 PMID:9168260 PMID:10051580 PMID:10496959 PMID:10496962 PMID:10575002 PMID:10581206 PMID:11042205 PMID:11559018 PMID:12097275 PMID:12117779 PMID:15331171 PMID:15596260 PMID:15667830 PMID:16054776 PMID:16903077 PMID:17183067 PMID:17275817 PMID:18205319 PMID:18678235 PMID:19276279 PMID:20507880 PMID:22595614 PMID:25110319 PMID:25697376 PMID:26945725 PMID:27869817 PMID:27891153 PMID:32159784 PMID:32553695 PMID:33759307 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases activity multiple interactions increases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1A2 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of CYP1A2 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A2 protein 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A2 mRNA]; 3-(3-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1A2 protein]; 3-(3-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A2 mRNA]; [CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A2 mRNA]; S-sulindac inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A2 mRNA] CYP1A2 protein results in increased activity of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:8961944 PMID:15606143 PMID:16054776 PMID:17183067 PMID:18678235 PMID:19276279 PMID:25110319 PMID:36863560 More...
|
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases activity increases metabolic processing increases expression multiple interactions affects response to substance increases response to substance |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1B1 protein CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA 2'-hydroxychalcone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; 2,4,3',5'-tetramethoxystilbene inhibits the reaction [[CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] which results in increased expression of TP53 protein modified form]; 2,4,3',5'-tetramethoxystilbene inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; 3-(3-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1B1 protein]; 3-(3-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; 5-androstene-16-fluoro-17-one inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [[benzo(c)phenanthrene results in increased expression of CYP1B1 protein] promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]] which results in increased chemical synthesis of 9,10-Dimethyl-1,2-benzanthracene analog; [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] which results in increased expression of TP53 protein modified form; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] which results in increased expression of TP53 protein modified form]; alpha-naphthoflavone inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; CYP1B1 protein results in increased metabolism of and results in increased activity of 9,10-Dimethyl-1,2-benzanthracene; Eugenol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; Eugenol inhibits the reaction [CYP1B1 protein results in increased metabolism of and results in increased activity of 9,10-Dimethyl-1,2-benzanthracene]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 protein]; S-sulindac inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 protein Estradiol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; POMC protein promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] 1-ethynylpyrene inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of CYP1B1 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Dietary Fats] results in decreased expression of CYP1B1 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of AHRR mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of CREB3L3 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of CXCL10 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of CYP1A1 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of EGR2 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of ERDR1X mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of HBB-B1 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of HOXB6 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of HSPA1A mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of IL6 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of NR4A1 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of POLR2A mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of RAG1 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of SOX19 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of SPP1 mRNA; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of TNF mRNA; [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Glucaric Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Glucaric Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Resveratrol co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; alpha-naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1B1 protein]; benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; chelerythrine inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; CYP1B1 protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased cleavage of CASP3 protein]; CYP1B1 protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased phosphorylation of TRP53 protein]; Dehydroepiandrosterone inhibits the reaction [benz(a)anthracene promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]]; Dehydroepiandrosterone inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; Dehydroepiandrosterone inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]]; pifithrin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1B1 protein]; POR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 protein]; PRKCB protein inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; PRKCB protein inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]]; pyrene inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP1B1 protein]; Tetrachlorodibenzodioxin promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; Tetradecanoylphorbol Acetate inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; Tetradecanoylphorbol Acetate inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]] 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of CYP1B1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 protein CYP1B1 protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene; CYP1B1 results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene CYP1B1 protein results in increased activity of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:7505439 PMID:7588239 PMID:8033136 PMID:8674863 PMID:9168260 PMID:10037446 PMID:10497882 PMID:10581206 PMID:11323178 PMID:11376689 PMID:11559018 PMID:12097275 PMID:12117779 PMID:15331171 PMID:15580705 PMID:15596260 PMID:15606143 PMID:15667830 PMID:15843505 PMID:17183067 PMID:17275817 PMID:17442664 PMID:18205319 PMID:19276279 PMID:19750107 PMID:20103723 PMID:20171256 PMID:21252291 PMID:22595614 PMID:25110319 PMID:26945725 PMID:27891153 PMID:32159784 PMID:32553695 PMID:35908932 More...
|
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases activity multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP2B1 protein beta-Naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP2B1 protein] |
CTD |
PMID:16054776 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases activity multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP2B2 protein beta-Naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of CYP2B2 protein] |
CTD |
PMID:16054776 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
CYP2B6 protein results in increased metabolism of and results in increased activity of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:32159784 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions increases expression |
ISO |
CYP2C19 protein results in increased metabolism of and results in increased activity of 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP2C29 mRNA |
CTD |
PMID:32159784 PMID:38307155 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases response to substance |
ISO |
CYP2D6 protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:20507880 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects response to substance increases expression |
ISO EXP |
CYP2E1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP2E1 mRNA |
CTD |
PMID:18622027 PMID:24576726 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:19713358 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases response to substance |
ISO |
CYP3A4 protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:20507880 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of DARS1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116
|
|
G |
Dazl |
deleted in azoospermia-like |
decreases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DAZL mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of DAZL mRNA AHR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DAZL mRNA]; alpha-naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DAZL mRNA] |
CTD |
PMID:20562217 |
|
NCBI chr 9:10,695,593...10,712,330
Ensembl chr 9:10,695,592...10,712,323
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of DBI mRNA |
CTD |
PMID:12376462 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Dchs1 |
dachsous cadherin-related 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of DCHS1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:160,104,931...160,138,958
Ensembl chr 1:160,104,931...160,124,808
|
|
G |
Dcn |
decorin |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of DCN protein |
CTD |
PMID:22248470 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of DCXR mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of DDIT3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of DDIT4 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of DDIT4 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of DDIT4L mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Ddrgk1 |
DDRGK domain containing 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of DDRGK1 protein |
CTD |
PMID:38307155 |
|
NCBI chr 3:117,861,916...117,882,680
Ensembl chr 3:117,861,653...117,882,680
|
|
G |
Ddx21 |
DExD-box helicase 21 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of DDX21 protein |
CTD |
PMID:38307155 |
|
NCBI chr20:30,534,319...30,554,513
Ensembl chr20:30,534,319...30,554,543
|
|
G |
Ddx39b |
DExD-box helicase 39B |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of DDX39B protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of DDX39B protein |
CTD |
PMID:22248470 |
|
NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996
|
|
G |
Ddx4 |
DEAD-box helicase 4 |
decreases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DDX4 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of DDX4 mRNA AHR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DDX4 mRNA]; alpha-naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DDX4 mRNA] |
CTD |
PMID:20562217 |
|
NCBI chr 2:44,227,946...44,282,867
Ensembl chr 2:44,227,946...44,282,723
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of DDX5 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283
|
|
G |
Des |
desmin |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of DES mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DHCR7 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dicer1 |
dicer 1 ribonuclease III |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] |
CTD |
PMID:24792773 |
|
NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
|
|
G |
Dido1 |
death inducer-obliterator 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DIDO1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:167,772,535...167,825,894
Ensembl chr 3:167,772,770...167,817,218
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of DIO3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNAJB6 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnajc9 |
DnaJ heat shock protein family (Hsp40) member C9 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of DNAJC9 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
increases expression multiple interactions |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein |
CTD |
PMID:12097258 PMID:24792773 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dock9 |
dedicator of cytokinesis 9 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of DOCK9 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:98,611,518...98,883,306
Ensembl chr15:98,618,084...98,883,153
|
|
G |
Dok1 |
docking protein 1 |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of DOK1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:115,537,453...115,540,464
Ensembl chr 4:115,537,462...115,540,465
|
|
G |
Dpt |
dermatopontin |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of DPT mRNA |
CTD |
PMID:19480007 |
|
NCBI chr13:77,123,224...77,151,646
Ensembl chr13:77,123,115...77,151,639
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
|
|
G |
Dynll2 |
dynein light chain LC8-type 2 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of DYNLL2 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr10:72,767,035...72,785,824
Ensembl chr10:72,767,035...72,785,805
|
|
G |
Dyrk3 |
dual specificity tyrosine phosphorylation regulated kinase 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of DYRK3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr13:42,594,120...42,604,898
Ensembl chr13:42,594,121...42,604,778
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of E2F8 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ecrg4 |
ECRG4 augurin precursor |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ECRG4 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 9:45,992,954...46,012,605
Ensembl chr 9:45,992,954...46,012,595
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of EDA2R mRNA |
CTD |
PMID:32553695 |
|
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268
|
|
G |
Ednrb |
endothelin receptor type B |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EDNRB mRNA |
CTD |
PMID:19480007 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of EEF1A1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of EEF1A1 protein |
CTD |
PMID:12376462 PMID:20045496 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of EEF2 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EFEMP1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Efnb2 |
ephrin B2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of EFNB2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of EGFR mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EGFR mRNA |
CTD |
PMID:32553695 PMID:36863560 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of EGR1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of EGR2 mRNA |
CTD |
PMID:27891153 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of EI24 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit beta |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EIF2S2 protein |
CTD |
PMID:38307155 |
|
NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of EIF4B mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 7:133,206,637...133,228,436
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of EIF4G2 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
Eno1 |
enolase 1 |
multiple interactions increases expression decreases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of ENO1 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of ENO1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ENO1 protein |
CTD |
PMID:12376462 PMID:22248470 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ENOX1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749
|
|
G |
Enox2 |
ecto-NOX disulfide-thiol exchanger 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ENOX2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr X:128,270,941...128,593,074
Ensembl chr X:128,271,074...128,593,039
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ENPP2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Epb41l4b |
erythrocyte membrane protein band 4.1 like 4B |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of EPB41L4B mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 5:71,691,706...71,852,583
Ensembl chr 5:71,694,331...71,851,990
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
multiple interactions increases expression decreases expression affects response to substance increases response to substance |
ISO EXP |
EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of EPHX1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of EPHX1 protein 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EPHX1 mRNA EPHX1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene EPHX1 protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene; EPHX1 results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene [cyclohexene oxide results in decreased activity of EPHX1 protein] which results in decreased susceptibility to 9,10-Dimethyl-1,2-benzanthracene; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; EPHX1 protein results in increased metabolism of and results in increased activity of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:8961944 PMID:11323178 PMID:12376462 PMID:15331171 PMID:17204581 PMID:17442664 PMID:19027032 PMID:24576726 More...
|
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Epo |
erythropoietin |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EPO mRNA |
CTD |
PMID:19502547 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
decreases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA [epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]; [theaflavin co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]; epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA] |
CTD |
PMID:23717041 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of ERP29 protein |
CTD |
PMID:22248470 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of ESCO2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306 Ensembl chr15:40,034,568...40,055,306
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression multiple interactions |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ESR1 protein 9,10-Dimethyl-1,2-benzanthracene binds to and results in increased activity of ESR1 protein [Estradiol co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in decreased expression of ESR1 protein; [Methylnitrosourea co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in decreased expression of ESR1 protein |
CTD |
PMID:16891317 PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene binds to and results in increased activity of ESR2 protein 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ESR2 mRNA |
CTD |
PMID:33049310 PMID:36863560 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of EVI2A mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843
|
|
G |
Exoc3l4 |
exocyst complex component 3-like 4 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EXOC3L4 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 6:130,452,680...130,466,684
Ensembl chr 6:130,452,661...130,466,683
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[sodium arsenite results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of EZH2 protein |
CTD |
PMID:35364107 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Ezr |
ezrin |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of EZR protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of EZR mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of EZR protein |
CTD |
PMID:12376462 PMID:22248470 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of FAS mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of FASN protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of FASN protein |
CTD |
PMID:22248470 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbn2 |
fibrillin 2 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FBN2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr18:51,499,670...51,703,976
Ensembl chr18:51,499,737...51,703,976
|
|
G |
Fcgbp |
Fc gamma binding protein |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of FCGBP protein |
CTD |
PMID:38307155 |
|
NCBI chr 1:83,374,979...83,413,082
Ensembl chr 1:83,372,127...83,413,083
|
|
G |
Fdps |
farnesyl diphosphate synthase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of FDPS mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fga |
fibrinogen alpha chain |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FGA protein |
CTD |
PMID:38307155 |
|
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fhit |
fragile histidine triad diadenosine triphosphatase |
decreases expression increases methylation |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FHIT mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FHIT protein 9,10-Dimethyl-1,2-benzanthracene results in increased methylation of FHIT intron; 9,10-Dimethyl-1,2-benzanthracene results in increased methylation of FHIT promoter |
CTD |
PMID:15937960 |
|
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of FHL2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fhod3 |
formin homology 2 domain containing 3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of FHOD3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr18:15,993,079...16,425,796
Ensembl chr18:15,993,324...16,425,796
|
|
G |
Fip1l1 |
factor interacting with PAPOLA and CPSF1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FIP1L1 protein |
CTD |
PMID:38307155 |
|
NCBI chr14:33,615,210...33,675,742
Ensembl chr14:33,617,720...33,675,708
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions decreases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of FN1 protein 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FN1 mRNA |
CTD |
PMID:12376462 PMID:22248470 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA; [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Glucaric Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Glucaric Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Resveratrol co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA]]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA]] |
CTD |
PMID:20103723 PMID:37352108 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of FOSL1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOSL1 protein [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of FOSL1 mRNA |
CTD |
PMID:20025956 PMID:32553695 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxa2 |
forkhead box A2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOXA2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOXA2 protein |
CTD |
PMID:36863560 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Foxn3 |
forkhead box N3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOXN3 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 6:118,462,018...118,842,442
Ensembl chr 6:118,466,025...118,842,401
|
|
G |
Foxo3 |
forkhead box O3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FOXO3 protein |
CTD |
PMID:21785161 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Frat2 |
FRAT regulator of WNT signaling pathway 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of FRAT2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:240,654,120...240,656,449
Ensembl chr 1:240,654,137...240,656,517
|
|
G |
Fth1 |
ferritin heavy chain 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FTH1 protein |
CTD |
PMID:38307155 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of FURIN mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fus |
Fus RNA binding protein |
affects expression decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene affects the expression of FUS mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of FUS mRNA |
CTD |
PMID:19480007 PMID:21785161 |
|
NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of G3BP1 protein |
CTD |
PMID:38307155 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions increases expression |
ISO |
[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of GADD45A mRNA]; [theaflavin co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of GADD45A mRNA]; epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of GADD45A mRNA] 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of GADD45A mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of GADD45A mRNA |
CTD |
PMID:23717041 PMID:32553695 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt13 |
polypeptide N-acetylgalactosaminyltransferase 13 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of GALNT13 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:38,903,695...39,560,683
Ensembl chr 3:38,974,490...39,558,803
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression increases expression multiple interactions |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GAPDH mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of GAPDH protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of GAPDH protein |
CTD |
PMID:19502547 PMID:22248470 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gas5 |
growth arrest specific 5 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GAS5 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr13:73,303,611...73,306,932
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of GBE1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210
|
|
G |
Gbp5 |
guanylate binding protein 5 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GBP5 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:231,237,748...231,257,071
Ensembl chr 2:231,237,748...231,257,061
|
|
G |
Gcat |
glycine C-acetyltransferase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GCAT protein |
CTD |
PMID:38307155 |
|
NCBI chr 7:110,595,126...110,601,474
Ensembl chr 7:110,595,091...110,601,473
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
increases expression decreases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of GCHFR mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GCHFR protein [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of GCHFR mRNA |
CTD |
PMID:32553695 PMID:38307155 |
|
NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080
|
|
G |
Gda |
guanine deaminase |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GDA mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of GDF15 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Get3 |
guided entry of tail-anchored proteins factor 3, ATPase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GET3 mRNA |
CTD |
PMID:38307155 |
|
NCBI chr19:23,130,109...23,138,196
Ensembl chr19:23,130,109...23,138,193
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GGT1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of GGTA1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:18,732,985...18,824,916
Ensembl chr 3:18,732,991...18,809,908
|
|
G |
Gh1 |
growth hormone 1 |
decreases response to substance |
EXP |
GH1 gene mutant form results in decreased susceptibility to 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:12082019 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gimap5 |
GTPase, IMAP family member 5 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GIMAP5 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:77,693,417...77,701,025
Ensembl chr 4:77,687,564...77,703,086
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions decreases expression increases expression |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Benzoyl Peroxide] affects the expression of GJA1 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Benzoyl Peroxide] results in increased expression of GJA1 mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of GJA1 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of GJA1 mRNA; A gene mutant form affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 mRNA] 9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Cycloheximide results in decreased expression of GJA1 protein]; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of and results in decreased stability of GJA1 mRNA; Chir 99021 promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 mRNA]; Chir 99021 promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 protein]; Dactinomycin promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 mRNA]; pyrazolanthrone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of GJA1 protein |
CTD |
PMID:7586191 PMID:24269759 PMID:25447408 PMID:36863560 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
decreases expression multiple interactions increases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA4 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA4 protein 9,10-Dimethyl-1,2-benzanthracene affects the reaction [A gene mutant form results in decreased expression of GJA4 protein]; [A gene mutant form co-treated with 9,10-Dimethyl-1,2-benzanthracene] affects the expression of GJA4 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of GJA4 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of GJA4 protein |
CTD |
PMID:24269759 PMID:25447408 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Benzoyl Peroxide] affects the expression of GJB2 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of GJB2 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of GJB2 mRNA |
CTD |
PMID:7586191 |
|
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gjb5 |
gap junction protein, beta 5 |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of GJB5 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of GJB5 mRNA |
CTD |
PMID:7586191 PMID:32553695 |
|
NCBI chr 5:139,680,670...139,683,588
Ensembl chr 5:139,680,671...139,683,583
|
|
G |
Gls |
glutaminase |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GLS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gmds |
GDP-mannose 4, 6-dehydratase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of GMDS mRNA |
CTD |
PMID:32553695 |
|
NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961
|
|
G |
Gng12 |
G protein subunit gamma 12 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GNG12 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712
|
|
G |
Gp2 |
glycoprotein 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GP2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:173,797,057...173,812,619
Ensembl chr 1:173,797,057...173,812,619
|
|
G |
Gpc6 |
glypican 6 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of GPC6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:94,030,218...95,027,883
Ensembl chr15:94,029,884...95,024,006
|
|
G |
Gphn |
gephyrin |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of GPHN mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612
|
|
G |
Gpr68 |
G protein-coupled receptor 68 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GPR68 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 6:120,135,620...120,166,089
Ensembl chr 6:120,135,436...120,166,089
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of GPRC5A mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
affects activity decreases activity multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene affects the activity of GPT protein 9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GPT protein Vitamin K affects the reaction [9,10-Dimethyl-1,2-benzanthracene affects the activity of GPT protein] |
CTD |
PMID:32623939 PMID:33063951 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases activity |
EXP |
brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GPX1 protein] |
CTD |
PMID:30027798 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GPX2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of GPX2 protein |
CTD |
PMID:18056462 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GPX3 mRNA |
CTD |
PMID:38307155 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases expression decreases activity |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with argemone oil]] results in decreased activity of GSR protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of GSR protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased activity of GSR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with argemone oil] results in decreased activity of GSR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of GSR protein; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GSR protein]; geraniol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GSR protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSR protein allyl isothiocyanate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSR protein]; brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSR protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSR protein]; zingerone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSR protein] |
CTD |
PMID:20691676 PMID:23033690 PMID:24995432 PMID:25744308 PMID:30027798 PMID:31476248 PMID:33347706 More...
|
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gss |
glutathione synthetase |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of GSS mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases activity multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSTA1 protein brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSTA1 protein] |
CTD |
PMID:30027798 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta3l1 |
glutathione S-transferase alpha 3 like 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GSTA3L1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 9:23,619,691...23,628,517
Ensembl chr 9:23,620,010...23,632,333
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects response to substance increases expression decreases expression multiple interactions |
EXP |
GSTP1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene results in increased expression of GSTP1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GSTP1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of GSTP1 protein |
CTD |
PMID:12097258 PMID:22406437 PMID:24576726 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gtdc1 |
glycosyltransferase-like domain containing 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of GTDC1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:28,766,640...29,161,668
Ensembl chr 3:28,766,645...29,162,271
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of GTSE1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
H19 |
H19 imprinted maternally expressed transcript |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of H19 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
|
|
G |
H1f4 |
H1.4 linker histone, cluster member |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of H1F4 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of H1F4 protein |
CTD |
PMID:22248470 |
|
NCBI chr17:41,486,574...41,487,355
Ensembl chr17:41,486,560...41,487,403
|
|
G |
H2ac18 |
H2A clustered histone 18 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of H2AC18 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of H2AC18 protein |
CTD |
PMID:22248470 |
|
NCBI chr 2:183,808,398...183,808,992
|
|
G |
H2ax |
H2A.X variant histone |
increases expression increases phosphorylation multiple interactions |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of H2AX protein 9,10-Dimethyl-1,2-benzanthracene results in increased phosphorylation of H2AX protein 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of H2AX protein modified form; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of H2AX protein A gene mutant form affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of H2AX protein] |
CTD |
PMID:23969067 PMID:25448685 PMID:32553695 PMID:34510228 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hal |
histidine ammonia lyase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with argemone oil]] results in decreased activity of HAL protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of HAL protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in decreased activity of HAL protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with argemone oil] results in decreased activity of HAL protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of HAL protein |
CTD |
PMID:20691676 |
|
NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of HAS2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HBA1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392 Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of HBB-B1 mRNA |
CTD |
PMID:27891153 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of HBEGF mRNA |
CTD |
PMID:32553695 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hdac1 |
histone deacetylase 1 |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] |
CTD |
PMID:24792773 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hells |
helicase, lymphoid specific |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of HELLS protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases activity affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased activity of HIF1A protein 9,10-Dimethyl-1,2-benzanthracene affects the expression of HIF1A mRNA |
CTD |
PMID:19502547 PMID:21785161 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hist1h2bq |
histone cluster 1 H2B family member Q |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of HIST1H2BQ protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of HIST1H2BQ protein |
CTD |
PMID:22248470 |
|
NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153 Ensembl chr17:41,429,164...41,442,153 Ensembl chr17:41,429,164...41,442,153
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 protein betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HMOX1 protein] |
CTD |
PMID:12097258 PMID:24995432 PMID:33759307 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of HNRNPA2B1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HNRNPD protein |
CTD |
PMID:38307155 |
|
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of HNRNPK mRNA |
CTD |
PMID:21785161 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of HNRNPM protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of HNRNPM protein |
CTD |
PMID:22248470 |
|
NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762
|
|
G |
Hoxb6 |
homeo box B6 |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of HOXB6 mRNA |
CTD |
PMID:27891153 |
|
NCBI chr10:81,258,726...81,267,458
Ensembl chr10:81,265,056...81,267,449
|
|
G |
Hp |
haptoglobin |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of HP mRNA |
CTD |
PMID:32553695 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions increases mutagenesis increases response to substance |
ISO |
4-octylphenol affects the reaction [HRAS protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene]; Estradiol affects the reaction [HRAS protein results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene] 9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene [9,10-Dimethyl-1,2-benzanthracene co-treated with Benzoyl Peroxide] results in increased expression of HRAS mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Benzoyl Peroxide] results in increased mutagenesis of HRAS gene; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate co-treated with mezerein] results in increased expression of HRAS mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of HRAS mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased mutagenesis of HRAS gene; [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Glucaric Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Glucaric Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Resveratrol co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene co-treated with geraniol] affects the localization of HRAS protein; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of HRAS protein |
CTD |
PMID:1375869 PMID:3115617 PMID:11241758 PMID:11376698 PMID:12117780 PMID:20103723 PMID:22760862 More...
|
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hrg |
histidine-rich glycoprotein |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of HRG protein |
CTD |
PMID:38307155 |
|
NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of HSP90AB1 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of HSP90AB1 protein |
CTD |
PMID:22248470 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of HSPA1A mRNA |
CTD |
PMID:27891153 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of HSPA5 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of HSPA5 protein |
CTD |
PMID:22248470 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of HSPA8 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
affects expression decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene affects the expression of HSPD1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HSPD1 mRNA |
CTD |
PMID:12097258 PMID:21785161 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of HSPE1 mRNA |
CTD |
PMID:12097258 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Hspg2 |
heparan sulfate proteoglycan 2 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of HSPG2 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ICAM1 mRNA |
CTD |
PMID:12097258 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ID3 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of IER3 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of IER3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227
|
|
G |
Ift70b |
intraflagellar transport 70B |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of IFT70B protein |
CTD |
PMID:38307155 |
|
NCBI chr 3:60,855,809...60,858,380
Ensembl chr 3:60,855,575...60,858,389
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
IGF1 protein results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Benzoyl Peroxide]; IGF1 protein results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with chrysarobin]; IGF1 protein results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Okadaic Acid]; IGF1 protein results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] |
CTD |
PMID:10365914 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2 |
insulin-like growth factor 2 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IGF2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Igsf10 |
immunoglobulin superfamily, member 10 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IGSF10 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:143,575,710...143,605,044
Ensembl chr 2:143,576,070...143,604,773
|
|
G |
Il10 |
interleukin 10 |
decreases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IL10 protein citronellol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IL10 protein] |
CTD |
PMID:31926054 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
IL12A results in decreased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] |
CTD |
PMID:22359662 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein] |
CTD |
PMID:36416909 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il17a |
interleukin 17A |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL17A mRNA Vitamin K inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL17A mRNA] |
CTD |
PMID:33063951 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il17ra |
interleukin 17 receptor A |
multiple interactions |
ISO |
IL17RA results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] |
CTD |
PMID:22359662 |
|
NCBI chr 4:153,667,534...153,690,174
Ensembl chr 4:153,667,534...153,690,174
|
|
G |
Il17rd |
interleukin 17 receptor D |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of IL17RD mRNA |
CTD |
PMID:32553695 |
|
NCBI chr16:2,228,438...2,295,122
Ensembl chr16:2,228,287...2,292,556
|
|
G |
Il18 |
interleukin 18 |
multiple interactions increases expression |
ISO |
dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL18 mRNA] |
CTD |
PMID:33347706 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA; [sodium arsenite co-treated with 9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL1A protein; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA]]; diacerein inhibits the reaction [[sodium arsenite co-treated with 9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL1A protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA]] |
CTD |
PMID:35364107 PMID:37352108 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL1B protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL1B mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL1B protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA]]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL1B mRNA]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL1B protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA]] tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL1B protein] |
CTD |
PMID:24995432 PMID:33347706 PMID:37352108 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
increases expression decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL1RL1 protein 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19480007 PMID:20025956 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of IL1RN mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
decreases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IL2 protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of IL2 protein; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA]]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA]]; Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of IL2 protein] |
CTD |
PMID:8931739 PMID:25770929 PMID:37352108 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il33 |
interleukin 33 |
increases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL33 mRNA |
CTD |
PMID:19480007 PMID:27869817 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4r |
interleukin 4 receptor |
multiple interactions increases expression |
ISO |
AHR mRNA promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL4RA] |
CTD |
PMID:27869817 |
|
NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to NFKB1 protein] which binds to IL6 promoter]]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides promotes the reaction [[RELA protein binds to NFKB1 protein] which binds to IL6 promoter]]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL6 protein; [CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of IL6 mRNA; [Glucaric Acid co-treated with Resveratrol] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA]; [Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA]; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased secretion of IL6 protein; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL6 protein]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA]]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL6 mRNA]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL6 protein]; Eugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased secretion of IL6 protein]; Glucaric Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA]]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of IL6 mRNA] 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of IL6 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL6 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL6 protein citronellol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL6 protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of IL6 protein] |
CTD |
PMID:14678569 PMID:20043298 PMID:23835587 PMID:24995432 PMID:27891153 PMID:31926054 PMID:32553695 PMID:32662567 PMID:33347706 PMID:37352108 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Immp2l |
inner mitochondrial membrane peptidase subunit 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of IMMP2L mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:58,070,035...58,970,165
Ensembl chr 6:58,070,283...58,969,840
|
|
G |
Impa1 |
inositol monophosphatase 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IMPA1 protein |
CTD |
PMID:38307155 |
|
NCBI chr 2:91,462,781...91,484,057
Ensembl chr 2:91,462,799...91,484,313
|
|
G |
Inhbb |
inhibin subunit beta B |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of INHBB mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of INHBB mRNA |
CTD |
PMID:32553695 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Insig1 |
insulin induced gene 1 |
affects expression decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene affects the expression of INSIG1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of INSIG1 mRNA |
CTD |
PMID:12376462 PMID:21785161 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Itgb3 |
integrin subunit beta 3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ITGB3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itgb6 |
integrin subunit beta 6 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ITGB6 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of ITPR1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Ivd |
isovaleryl-CoA dehydrogenase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IVD protein |
CTD |
PMID:38307155 |
|
NCBI chr 3:105,851,710...105,872,144
Ensembl chr 3:105,851,683...105,872,575
|
|
G |
Ivns1abp |
influenza virus NS1A binding protein |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of IVNS1ABP mRNA |
CTD |
PMID:21785161 |
|
NCBI chr13:63,427,040...63,446,701
Ensembl chr13:63,427,041...63,446,701
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of JCHAIN mRNA |
CTD |
PMID:19480007 |
|
NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,538,952...19,546,298
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of JUN protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA; [Glucaric Acid co-treated with Resveratrol] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; [Glucaric Acid co-treated with Ursolic Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA]]; Glucaric Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA]]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of JUN protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of JUN protein modified form |
CTD |
PMID:20025956 PMID:22406437 PMID:23835587 PMID:37352108 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 protein betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of KEAP1 protein] |
CTD |
PMID:24995432 PMID:33759307 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KIF1A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
|
|
G |
Kif21a |
kinesin family member 21A |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of KIF21A mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:122,062,523...122,179,051
Ensembl chr 7:122,062,537...122,178,999
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of KIT protein |
CTD |
PMID:24576726 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Kitlg |
KIT ligand |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KITLG mRNA |
CTD |
PMID:24576726 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Klf10 |
KLF transcription factor 10 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of KLF10 mRNA |
CTD |
PMID:12097258 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of KLF4 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klhl29 |
kelch-like family member 29 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of KLHL29 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:28,086,489...28,390,647
Ensembl chr 6:28,086,489...28,390,647
|
|
G |
Kmt2c |
lysine methyltransferase 2C |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of KMT2C mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:9,620,638...9,834,787
Ensembl chr 4:9,609,627...9,833,539
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of KNG1 protein |
CTD |
PMID:22248470 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Kng2 |
kininogen 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KNG2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Krt1 |
keratin 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KRT1 protein |
CTD |
PMID:38307155 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KRT10 protein |
CTD |
PMID:38307155 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Krt13 |
keratin 13 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KRT13 protein |
CTD |
PMID:38307155 |
|
NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084
|
|
G |
Krt19 |
keratin 19 |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KRT19 protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of KRT19 protein |
CTD |
PMID:22248470 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt5 |
keratin 5 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of KRT5 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of KRT5 mRNA |
CTD |
PMID:12376462 PMID:19480007 PMID:22248470 |
|
NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850
|
|
G |
Krt78 |
keratin 78 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of KRT78 protein |
CTD |
PMID:38307155 |
|
NCBI chr 7:133,074,193...133,081,536
Ensembl chr 7:133,074,215...133,082,021
|
|
G |
Krt8 |
keratin 8 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of KRT8 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of KRT8 protein |
CTD |
PMID:22248470 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:132,463,216...132,485,134
Ensembl chr 7:132,463,218...132,485,508
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LAMC2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lamtor2 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of LAMTOR2 protein |
CTD |
PMID:38307155 |
|
NCBI chr 2:174,008,556...174,011,950
Ensembl chr 2:174,008,548...174,013,013
|
|
G |
Large1 |
LARGE xylosyl- and glucuronyltransferase 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of LARGE mRNA |
CTD |
PMID:32553695 |
|
NCBI chr19:11,603,129...12,048,930
Ensembl chr19:11,603,129...12,048,930
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LCK mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Lgals3 |
galectin 3 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of LGALS3 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lgals7 |
galectin 7 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:84,148,612...84,152,016
Ensembl chr 1:84,150,252...84,152,015
|
|
G |
Lgr5 |
leucine rich repeat containing G protein coupled receptor 5 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of LGR5 mRNA |
CTD |
PMID:36863560 |
|
NCBI chr 7:51,087,059...51,221,882
Ensembl chr 7:51,088,239...51,222,446
|
|
G |
Limd1 |
LIM domain containing 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LIMD1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714
|
|
G |
Lin7a |
lin-7 homolog A, crumbs cell polarity complex component |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of LIN7A mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 7:42,586,704...42,742,609
Ensembl chr 7:42,586,719...42,730,550
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of LMNA protein |
CTD |
PMID:22248470 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression multiple interactions |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of LPL mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of LPL mRNA |
CTD |
PMID:12376462 PMID:32553695 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrrc59 |
leucine rich repeat containing 59 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of LRRC59 protein |
CTD |
PMID:38307155 |
|
NCBI chr10:79,572,295...79,586,953
Ensembl chr10:79,572,317...79,602,533
|
|
G |
Lsm4 |
LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LSM4 protein |
CTD |
PMID:38307155 |
|
NCBI chr16:18,755,481...18,761,106
Ensembl chr16:18,755,484...18,760,926
|
|
G |
Lsm6 |
LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LSM6 protein |
CTD |
PMID:38307155 |
|
NCBI chr19:29,098,254...29,112,858
Ensembl chr13:42,114,032...42,116,484 Ensembl chr19:42,114,032...42,116,484
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LSR mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 1:86,185,769...86,201,952
Ensembl chr 1:86,186,431...86,201,952
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of LSS mRNA |
CTD |
PMID:32553695 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Ltc4s |
leukotriene C4 synthase |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LTC4S mRNA |
CTD |
PMID:19480007 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of LY6E mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
|
|
G |
Lypd1 |
Ly6/Plaur domain containing 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of LYPD1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr13:37,326,459...37,368,515
Ensembl chr13:37,326,464...37,368,493
|
|
G |
Lyrm4 |
LYR motif containing 4 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of LYRM4 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr17:28,746,457...28,861,849
Ensembl chr17:28,746,469...28,861,750
|
|
G |
Lyve1 |
lymphatic vessel endothelial hyaluronan receptor 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of LYVE1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
|
|
G |
Maea |
macrophage erythroblast attacher, E3 ubiquitin ligase |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of MAEA mRNA |
CTD |
PMID:21785161 |
|
NCBI chr14:77,357,261...77,390,683
Ensembl chr14:77,357,264...77,390,671
|
|
G |
Mafb |
MAF bZIP transcription factor B |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MAFB mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Magi1 |
membrane associated guanylate kinase, WW and PDZ domain containing 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of MAGI1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO EXP |
[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased phosphorylation of MAPK1 protein; geraniol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased phosphorylation of MAPK1 protein] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK1 protein |
CTD |
PMID:22760862 PMID:36863560 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO EXP |
[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased phosphorylation of MAPK3 protein; geraniol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased phosphorylation of MAPK3 protein] betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK3 mRNA] |
CTD |
PMID:22760862 PMID:33759307 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK8 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK8 protein betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MAPK8 mRNA] |
CTD |
PMID:33759307 PMID:36863560 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of MAT2A mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MCM3 protein |
CTD |
PMID:20025956 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mdh2 |
malate dehydrogenase 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDH2 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of MDM2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA [epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]; [theaflavin co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]; theaflavin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA] |
CTD |
PMID:23717041 PMID:32553695 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Megf6 |
multiple EGF-like-domains 6 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MEGF6 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:164,738,272...164,839,142
Ensembl chr 5:164,738,352...164,839,139
|
|
G |
Mgarp |
mitochondria-localized glutamic acid-rich protein |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MGARP mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:135,431,283...135,439,425
Ensembl chr 2:135,431,283...135,439,612
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
MGMT protein results in decreased susceptibility to [Methylnitrosourea co-treated with 9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] |
CTD |
PMID:12663516 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgp |
matrix Gla protein |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MGP mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MIF mRNA |
CTD |
PMID:12376462 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504 Ensembl chr 4:12,790,902...12,799,504
|
|
G |
Mir203-2 |
microRNA 203-2 |
affects expression multiple interactions increases methylation |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] |
CTD |
PMID:24792773 |
|
NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656
|
|
G |
Misp3 |
MISP family member 3 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MISP3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr19:24,139,998...24,142,006
Ensembl chr19:24,140,033...24,142,631
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Estradiol results in increased expression of MKI67 mRNA]; [Estradiol co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of MKI67 protein; [Ruthenium binds to Phloretin] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MKI67 protein]; Plant Preparations inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Estradiol results in increased expression of MKI67 mRNA]] |
CTD |
PMID:16891317 PMID:26945725 PMID:34896434 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlf2 |
myeloid leukemia factor 2 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of MLF2 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 4:157,739,651...157,744,325
Ensembl chr 4:157,728,756...157,744,317
|
|
G |
Mme |
membrane metallo-endopeptidase |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MME mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MMP12 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MMP13 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MMP13 protein |
CTD |
PMID:19480007 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MMP14 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP2 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP2 protein]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP2 protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA]]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP2 protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA]] |
CTD |
PMID:37352108 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
decreases expression increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MMP7 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MMP7 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MMP7 protein |
CTD |
PMID:19480007 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
affects expression multiple interactions increases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene affects the expression of MMP9 mRNA [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA; [sodium arsenite results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of MMP9 protein; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA]]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA]] [9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride co-treated with Fluoxetine] affects the expression of MMP9 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride] affects the expression of MMP9 protein; [Ruthenium binds to Phloretin] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MMP9 protein]; Resveratrol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MMP9 protein] |
CTD |
PMID:12208745 PMID:21785161 PMID:31332895 PMID:34896434 PMID:35364107 PMID:37352108 More...
|
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with cumene hydroperoxide] results in increased activity of MPO protein 9,10-Dimethyl-1,2-benzanthracene results in increased activity of MPO protein |
CTD |
PMID:14972014 PMID:32623939 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MR1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
|
|
G |
Msra |
methionine sulfoxide reductase A |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of MSRA mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of COX1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt1 |
metallothionein 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MT1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mto1 |
mitochondrial tRNA translation optimization 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MTO1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 8:79,309,681...79,335,231
Ensembl chr 8:79,309,982...79,335,231
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MTOR protein modified form 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MTOR protein modified form |
CTD |
PMID:21785161 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc1 |
mucin 1, cell surface associated |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MUC1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYB mRNA |
CTD |
PMID:36863560 |
|
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC protein; Butyric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA]]; Eugenol inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC protein]; Glucaric Acid affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA]] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of MYC mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein |
CTD |
PMID:20537511 PMID:24792773 PMID:29663660 PMID:32553695 PMID:37352108 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh9 |
myosin, heavy chain 9 |
increases expression multiple interactions |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYH9 protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of MYH9 protein |
CTD |
PMID:22248470 |
|
NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457
|
|
G |
Mylk |
myosin light chain kinase |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of MYLK mRNA |
CTD |
PMID:32553695 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myod1 |
myogenic differentiation 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of MYOD1 mRNA |
CTD |
PMID:36863560 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
N4bp1 |
Nedd4 binding protein 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of N4BP1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr19:20,222,811...20,273,570
Ensembl chr19:20,222,776...20,273,570
|
|
G |
Ncald |
neurocalcin delta |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of NCALD mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of NCAM1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Ncmap |
noncompact myelin associated protein |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NCMAP mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:147,608,042...147,623,266
Ensembl chr 5:147,610,677...147,618,775
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NDUFB8 protein |
CTD |
PMID:38307155 |
|
NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817
|
|
G |
Nell1 |
neural EGFL like 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NELL1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nes |
nestin |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NES protein |
CTD |
PMID:38307155 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NETO2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:21,344,299...21,415,524
Ensembl chr19:21,344,289...21,417,023
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions increases activity decreases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NFE2L2 protein [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of NFE2L2 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of NFE2L2 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased activity of NFE2L2 protein betulin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFE2L2 protein |
CTD |
PMID:22406437 PMID:24995432 PMID:30114225 PMID:32553695 PMID:33759307 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to NFKB1 protein] which binds to IL6 promoter]]; 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides promotes the reaction [[RELA protein binds to NFKB1 protein] which binds to IL6 promoter]]; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NFKB1 protein; [Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NFKB1 protein]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA]]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA]] |
CTD |
PMID:14678569 PMID:23835587 PMID:37352108 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of and results in increased phosphorylation of NFKBIA protein; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NFKBIA protein modified form; dieckol affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NFKBIA protein]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased phosphorylation of NFKBIA protein]; Eugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NFKBIA protein modified form] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of NFKBIA mRNA citronellol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of NFKBIA mRNA] |
CTD |
PMID:20043298 PMID:31926054 PMID:33347706 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nid1 |
nidogen 1 |
affects expression decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene affects the expression of NID1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NID1 mRNA |
CTD |
PMID:19480007 PMID:21785161 |
|
NCBI chr17:86,085,133...86,158,272
Ensembl chr17:86,085,077...86,158,267
|
|
G |
Nipsnap2 |
nipsnap homolog 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NIPSNAP2 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr12:26,906,068...26,944,201
Ensembl chr12:26,911,723...26,944,166
|
|
G |
Nkg7 |
natural killer cell granule protein 7 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NKG7 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:93,844,748...93,845,975
Ensembl chr 1:93,844,902...93,845,983
|
|
G |
Nlrp5 |
NLR family, pyrin domain containing 5 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of NLRP5 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 1:67,778,037...67,810,941
Ensembl chr 1:67,777,948...68,023,736
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NOS2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of NOS2 protein [Maxepa co-treated with Calcitriol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of NOS2 mRNA]; citronellol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of NOS2 protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of NOS2 protein] [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NOS2 protein; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NOS2 protein; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NOS2 protein]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein]]; Eugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of NOS2 protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein]] |
CTD |
PMID:20043298 PMID:20599847 PMID:24995432 PMID:31926054 PMID:32662567 PMID:37352108 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of NOTCH1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch3 |
notch receptor 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of NOTCH3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Nppc |
natriuretic peptide C |
multiple interactions |
ISO |
Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP2 protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of TNF mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of VEGFA mRNA]]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of TNF mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of VEGFA mRNA]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP2 protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of and results in increased activity of MMP9 protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of CRP protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of FOS mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1A mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL1B mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL2 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of IL6 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of JUN mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP2 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MMP9 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of MYC mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NFKB1 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of NOS2 protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of TNF mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of VEGFA mRNA]] |
CTD |
PMID:37352108 |
|
NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of NPR3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955
|
|
G |
Nptx1 |
neuronal pentraxin 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NPTX1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr10:104,811,107...104,820,358
Ensembl chr10:104,811,403...104,820,367
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions decreases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased activity of NQO1 protein 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of NQO1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of NQO1 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of NQO1 protein; Metformin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of and results in increased activity of NQO1 protein]; Metformin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of NQO1 mRNA] acetylsalicylic acid lysinate promotes the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of NQO1 protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NQO1 mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NQO1 protein] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NQO1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NQO1 protein [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of NQO1 mRNA; Resveratrol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased activity of NQO1 protein] |
CTD |
PMID:18678235 PMID:18694800 PMID:24995432 PMID:25697376 PMID:32553695 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of NR2F1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of NR4A1 mRNA |
CTD |
PMID:27891153 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nsdhl |
NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of NSDHL mRNA |
CTD |
PMID:21785161 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsmf |
NMDA receptor synaptonuclear signaling and neuronal migration factor |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NSMF mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 3:7,861,846...7,870,615
Ensembl chr 3:7,861,872...7,870,614
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of NTF3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Nubpl |
NUBP iron-sulfur cluster assembly factor like |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of NUBPL mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:69,559,278...69,781,254
Ensembl chr 6:69,559,291...69,781,253
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of NUSAP1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of OGG1 mRNA Metformin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of OGG1 mRNA] |
CTD |
PMID:25697376 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Ogn |
osteoglycin |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of OGN mRNA |
CTD |
PMID:19480007 |
|
NCBI chr17:15,032,069...15,052,626
Ensembl chr17:15,032,069...15,052,739
|
|
G |
Olfml3 |
olfactomedin-like 3 |
multiple interactions |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of OLFML3 protein |
CTD |
PMID:22248470 |
|
NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:191,244,221...191,247,050
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of ORM1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Otor |
otoraplin |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of OTOR mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:130,415,339...130,418,601
Ensembl chr 3:130,415,339...130,418,601
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
affects expression multiple interactions |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene affects the expression of PABPC1 mRNA [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of PABPC1 protein |
CTD |
PMID:21785161 PMID:22248470 |
|
NCBI chr 7:67,777,438...67,789,731
Ensembl chr 7:67,777,381...67,789,744
|
|
G |
Padi4 |
peptidyl arginine deiminase 4 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PADI4 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 5:153,041,351...153,074,412
Ensembl chr 5:153,041,352...153,074,362
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PAPSS2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331
|
|
G |
Pard6g |
par-6 family cell polarity regulator gamma |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PARD6G mRNA |
CTD |
PMID:32553695 |
|
NCBI chr18:73,497,992...73,565,048
Ensembl chr18:73,498,021...73,565,029
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression multiple interactions increases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PARP1 mRNA 9,10-Dimethyl-1,2-benzanthracene promotes the reaction [A gene mutant form results in increased expression of PARP1 mRNA]; 9,10-Dimethyl-1,2-benzanthracene promotes the reaction [A gene mutant form results in increased expression of PARP1 protein] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PARP1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PARP1 protein |
CTD |
PMID:23969067 PMID:25448685 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcca |
propionyl-CoA carboxylase subunit alpha |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PCCA mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:99,627,955...99,969,555
Ensembl chr15:99,627,982...99,968,266
|
|
G |
Pcdh18 |
protocadherin 18 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PCDH18 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PCNA mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PCNA protein; [Glucaric Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA]; [Resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA]; [Resveratrol co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA]; [sodium arsenite results in increased susceptibility to [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of PCNA protein; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PCNA mRNA]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein]]; Eugenol inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PCNA protein]; Masoprocol affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PCNA protein]]; Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]; Tacrolimus affects the reaction [Tacrolimus affects the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] affects the expression of PCNA protein]] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA protein mithramycin A inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA protein] 9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Estradiol results in increased expression of PCNA mRNA]; Plant Preparations inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Estradiol results in increased expression of PCNA mRNA]]; Taurine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA protein] |
CTD |
PMID:20043298 PMID:20103723 PMID:22248470 PMID:25770929 PMID:26945725 PMID:27091720 PMID:29663660 PMID:32662567 PMID:35364107 PMID:37352108 More...
|
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCP4 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCP4 protein |
CTD |
PMID:19480007 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pcsk6 |
proprotein convertase subtilisin/kexin type 6 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PCSK6 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:119,428,978...119,627,626
Ensembl chr 1:119,429,265...119,627,596
|
|
G |
Pde1a |
phosphodiesterase 1A |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PDE1A mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde4dip |
phosphodiesterase 4D interacting protein |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PDE4DIP mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
increases expression increases expression |
EXP IEP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PDGFA mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PDGFA protein DMBA increases expression of Pdgfa mRNA and protein in rat mammary gland |
CTD RGD |
PMID:12376462 PMID:12376462 |
RGD:2292404 |
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
multiple interactions increases expression |
EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of PDIA3 protein 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PDIA3 protein |
CTD |
PMID:22248470 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PDK mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PEBP1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Penk |
proenkephalin |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PENK mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Pfkm |
phosphofructokinase, muscle |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PFKM mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PGD mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pglyrp1 |
peptidoglycan recognition protein 1 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of PGLYRP1 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 1:78,531,815...78,537,001
Ensembl chr 1:78,531,815...78,537,001
|
|
G |
Phb1 |
prohibitin 1 |
increases expression increases expression |
EXP IEP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PHB1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PHB1 protein DMBA increases expression of Phb1 mRNA and protein in rat mammary gland |
CTD RGD |
PMID:12376462 PMID:12376462 |
RGD:2292404 |
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PHEX protein |
CTD |
PMID:20025956 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PHLDA1 mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PHLDA1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
affects expression multiple interactions increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of PHLDA3 mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PHLDA3 mRNA 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PHLDA3 mRNA |
CTD |
PMID:21785161 PMID:32553695 |
|
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
multiple interactions increases mutagenesis |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of and results in decreased activity of PIGA protein; [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of and results in decreased activity of PIGA protein] which affects the localization of CD59 protein; [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of PIGA gene] which results in decreased expression of CD59 protein 9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of PIGA; 9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of PIGA gene |
CTD |
PMID:19965957 PMID:20202993 PMID:22923490 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pik3r5 |
phosphoinositide-3-kinase, regulatory subunit 5 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PIK3R5 protein |
CTD |
PMID:20025956 |
|
NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374
|
|
G |
Pitx1 |
paired-like homeodomain 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PITX1 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr17:8,794,134...8,800,292
Ensembl chr17:8,794,134...8,800,291
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plg |
plasminogen |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PLG protein |
CTD |
PMID:38307155 |
|
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression increases expression |
EXP IEP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PLK2 mRNA DMBA increases expression of Plk2 mRNA and protein in rat mammary gland 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PLK2 mRNA |
CTD RGD |
PMID:12376462 PMID:32553695 PMID:12376462 |
RGD:2292404 |
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plxna2 |
plexin A2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PLXNA2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979
|
|
G |
Pnisr |
PNN interacting serine and arginine rich protein |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PNISR mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 5:35,395,965...35,422,852
Ensembl chr 5:35,395,965...35,422,844
|
|
G |
Polm |
DNA polymerase mu |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of POLM mRNA |
CTD |
PMID:19480007 |
|
NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086
|
|
G |
Polr2a |
RNA polymerase II subunit A |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of POLR2A mRNA |
CTD |
PMID:27891153 |
|
NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
POMC protein promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene] |
CTD |
PMID:7588239 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases abundance |
ISO |
POR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 protein] POR protein results in decreased abundance of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:22595614 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppfibp2 |
PPFIA binding protein 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PPFIBP2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:161,504,774...161,687,339
Ensembl chr 1:161,504,890...161,655,212
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PPM1D mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Ppm1l |
protein phosphatase, Mg2+/Mn2+ dependent, 1L |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PPM1L mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:153,566,653...153,839,434
Ensembl chr 2:153,566,653...153,839,434
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of PPP1CB mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961
|
|
G |
Ppp2r1b |
protein phosphatase 2 scaffold subunit A beta |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PPP2R1B mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PPP2R2B mRNA |
CTD |
PMID:19480007 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prdm1 |
PR/SET domain 1 |
decreases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PRDM1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PRDM1 mRNA AHR protein affects the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PRDM1 mRNA]; alpha-naphthoflavone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PRDM1 mRNA] |
CTD |
PMID:20562217 |
|
NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
|
|
G |
Prdm6 |
PR/SET domain 6 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PRDM6 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr18:46,904,115...47,008,482
Ensembl chr18:46,904,127...47,007,823
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PRDX2 protein |
CTD |
PMID:20045496 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions increases expression |
EXP |
Ghee inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PRKCA mRNA] |
CTD |
PMID:21088903 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
PRKCB protein inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; PRKCB protein inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]] |
CTD |
PMID:10037446 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkce |
protein kinase C, epsilon |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PRKCE mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions decreases expression increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [A gene mutant form results in decreased expression of PRKDC mRNA] 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PRKDC mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PRKDC protein |
CTD |
PMID:25448685 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Prl |
prolactin |
increases metabolic processing increases secretion multiple interactions |
EXP |
PRL protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene results in increased secretion of PRL protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Estradiol] results in increased secretion of PRL protein; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] affects the metabolism of 9,10-Dimethyl-1,2-benzanthracene |
CTD |
PMID:3141044 PMID:8674863 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Procr |
protein C receptor |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PROCR mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Prr15 |
proline rich 15 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PRR15 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of PSAT1 protein |
CTD |
PMID:38307155 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Psrc1 |
proline and serine rich coiled-coil 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PSRC1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874
|
|
G |
Ptbp1 |
polypyrimidine tract binding protein 1 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTBP1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
multiple interactions increases response to substance |
ISO |
celecoxib inhibits the reaction [PTGER1 results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene]; PTGS2 gene mutant form inhibits the reaction [PTGER1 results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene] |
CTD |
PMID:21739481 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 protein; [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PTGS2 mRNA; [epigallocatechin gallate co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA]; [Resveratrol co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 protein; [theaflavin co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA]; [Ursolic Acid co-treated with Glucaric Acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; amarogentin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]; beta-elemene inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 protein]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA]; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA]]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]]; dieckol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA]; Eugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 protein]; Glucaric Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 mRNA]]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]]; Plant Extracts inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of PTGS2 protein]; PTGS2 gene mutant form inhibits the reaction [PTGER1 results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA]; theaflavin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA]; Ursolic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 mRNA] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 protein 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PTGS2 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA [Estradiol co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of PTGS2 protein; citronellol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 protein]; Ghee inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 protein] |
CTD |
PMID:12208745 PMID:16517061 PMID:16891317 PMID:20043298 PMID:21623034 PMID:21739481 PMID:23717041 PMID:23835587 PMID:24995432 PMID:31926054 PMID:32553695 PMID:32662567 PMID:33347706 PMID:37352108 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptms |
parathymosin |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of PTMS mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 4:157,722,384...157,726,575
Ensembl chr 4:157,722,386...157,727,009
|
|
G |
Ptn |
pleiotrophin |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PTN mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PTP4A1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964
|
|
G |
Ptpn13 |
protein tyrosine phosphatase, non-receptor type 13 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PTPN13 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563
|
|
G |
Ptpn22 |
protein tyrosine phosphatase, non-receptor type 22 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTPN22 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:191,366,761...191,414,782
Ensembl chr 2:191,366,808...191,414,779
|
|
G |
Ptprcap |
protein tyrosine phosphatase, receptor type, C-associated protein |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTPRCAP mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 1:201,449,133...201,451,293
Ensembl chr 1:201,449,113...201,451,288
|
|
G |
Ptprg |
protein tyrosine phosphatase, receptor type, G |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PTPRG mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:12,871,706...13,552,186
Ensembl chr15:12,871,721...13,554,094
|
|
G |
Ptprm |
protein tyrosine phosphatase, receptor type, M |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of PTPRM mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 9:106,639,573...107,343,698
Ensembl chr 9:106,639,573...107,343,698
|
|
G |
Ptx3 |
pentraxin 3 |
increases expression multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of PTX3 mRNA [9,10-Dimethyl-1,2-benzanthracene results in increased activity of AHR protein] which results in increased expression of PTX3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Rab12 |
RAB12, member RAS oncogene family |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of RAB12 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 9:106,480,301...106,506,895
Ensembl chr 9:106,480,301...106,506,910
|
|
G |
Rabgap1l |
RAB GTPase activating protein 1-like |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of RABGAP1L mRNA |
CTD |
PMID:32553695 |
|
NCBI chr13:72,464,114...73,059,845
Ensembl chr13:72,468,110...73,059,984
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression multiple interactions |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 mRNA A gene mutant form affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 protein]; A gene mutant form inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 mRNA] 9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of RAD51 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51 protein |
CTD |
PMID:23969067 PMID:25448685 PMID:32553695 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rad51ap1 |
RAD51 associated protein 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAD51AP1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524
|
|
G |
Rad51b |
RAD51 paralog B |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of RAD51B mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:98,096,525...98,640,988
Ensembl chr 6:98,098,868...98,640,979
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of RAF1 protein; geraniol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of RAF1 protein] |
CTD |
PMID:22760862 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rag1 |
recombination activating 1 |
multiple interactions |
ISO |
[CYP1B1 protein affects the susceptibility to 9,10-Dimethyl-1,2-benzanthracene] which affects the expression of RAG1 mRNA |
CTD |
PMID:27891153 |
|
NCBI chr 3:87,917,061...87,928,158
Ensembl chr 3:87,917,004...87,928,291
|
|
G |
Ran |
RAN, member RAS oncogene family |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of RAN mRNA |
CTD |
PMID:12376462 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of RARRES2 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of RB1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbp1 |
retinol binding protein 1 |
increases expression increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of RBP1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of RBP1 protein DMBA increases expression of Rbp1 mRNA and protein in rat mammary gland |
CTD RGD |
PMID:12376462 PMID:12376462 |
RGD:2292404 |
NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743
|
|
G |
Rbp4 |
retinol binding protein 4 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of RBP4 protein |
CTD |
PMID:38307155 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to NFKB1 protein] which binds to IL6 promoter]] |
CTD |
PMID:14678569 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [Lipopolysaccharides promotes the reaction [[RELA protein binds to NFKB1 protein] which binds to IL6 promoter]]; [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein; [Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of RELA protein; Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein]; Cisplatin promotes the reaction [NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein]]; Eugenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of RELA protein]; NPPC protein inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein]; NPPC protein promotes the reaction [Cisplatin inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of RELA protein]] citronellol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RELA protein]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RELA mRNA]; tangeretin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of RELA protein] 9,10-Dimethyl-1,2-benzanthracene results in increased expression of RELA mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of RELA protein |
CTD |
PMID:14678569 PMID:20043298 PMID:24995432 PMID:31926054 PMID:37352108 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rerg |
RAS-like, estrogen-regulated, growth-inhibitor |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of RERG mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 4:169,981,634...170,089,777
Ensembl chr 4:169,982,279...170,089,715
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of RHOA protein |
CTD |
PMID:38307155 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Ripply3 |
ripply transcriptional repressor 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of RIPPLY3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:33,648,471...33,656,587
Ensembl chr11:33,648,486...33,656,584
|
|
G |
Rnd1 |
Rho family GTPase 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of RND1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Rnf213 |
ring finger protein 213 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of RNF213 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:104,656,329...104,755,669
Ensembl chr10:104,656,883...104,757,918
|
|
G |
Rpl15 |
ribosomal protein L15 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of RPL15 protein |
CTD |
PMID:38307155 |
|
NCBI chr15:7,503,883...7,507,166
Ensembl chr15:7,503,883...7,507,165 Ensembl chr12:7,503,883...7,507,165
|
|
G |
Rpl6 |
ribosomal protein L6 |
increases expression |
EXP ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of RPL6 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of RPL6 protein |
CTD |
PMID:12376462 PMID:38307155 |
|
NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921
|
|
G |
Rpl8 |
ribosomal protein L8 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of RPL8 protein |
CTD |
PMID:38307155 |
|
NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482 Ensembl chr 3:108,622,324...108,628,482
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases expression increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of RPS6 mRNA 9,10-Dimethyl-1,2-benzanthracene results in increased expression of RPS6 mRNA |
CTD |
PMID:12097258 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rpsa |
ribosomal protein SA |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of RPSA protein |
CTD |
PMID:22248470 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of RRM2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
affects expression decreases expression multiple interactions |
ISO EXP |
9,10-Dimethyl-1,2-benzanthracene affects the expression of S100A8 mRNA 9,10-Dimethyl-1,2-benzanthracene results in decreased expression of S100A8 protein [9,10-Dimethyl-1,2-benzanthracene co-treated with Isoflavones] results in increased expression of S100A8 protein |
CTD |
PMID:21785161 PMID:22248470 PMID:38307155 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of S100A9 protein |
CTD |
PMID:38307155 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of S1PR1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 2:206,309,715...206,314,070
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
Sac3d1 |
SAC3 domain containing 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of SAC3D1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 1:203,414,184...203,416,563
Ensembl chr 1:203,414,187...203,416,604
|
|
G |
Sacs |
sacsin molecular chaperone |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of SACS mRNA |
CTD |
PMID:32553695 |
|
NCBI chr15:35,285,783...35,370,335
Ensembl chr15:35,285,782...35,370,335
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of SCARB1 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of SCD mRNA |
CTD |
PMID:12097258 PMID:12376462 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scfd2 |
sec1 family domain containing 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of SCFD2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr14:33,683,348...34,008,232
Ensembl chr14:33,683,273...34,008,213
|
|
G |
Scmh1 |
Scm polycomb group protein homolog 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of SCMH1 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 5:133,991,167...134,115,893
Ensembl chr 5:133,990,520...134,122,105
|
|
G |
Sdc4 |
syndecan 4 |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of SDC4 mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Sdcbp |
syndecan binding protein |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of SDCBP mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
affects expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene affects the expression of SEC23A mRNA |
CTD |
PMID:21785161 |
|
NCBI chr 6:76,658,793...76,706,125
Ensembl chr 6:76,658,427...76,706,035
|
|
G |
Selenop |
selenoprotein P |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of SELENOP mRNA |
CTD |
PMID:12376462 |
|
NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of SFN mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sfpq |
splicing factor proline and glutamine rich |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of SFPQ protein |
CTD |
PMID:38307155 |
|
NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of SFRP2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of SLC12A2 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc13a3 |
solute carrier family 13 member 3 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of SLC13A3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 3:154,141,878...154,204,604
Ensembl chr 3:154,141,872...154,204,606
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of SLC16A2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of SLC16A3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc19a2 |
solute carrier family 19 member 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of SLC19A2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of SLC1A3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc25a10 |
solute carrier family 25 member 10 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of SLC25A10 mRNA |
CTD |
PMID:12376462 |
|
NCBI chr10:105,765,598...105,775,159
Ensembl chr10:105,765,372...105,773,556
|
|
G |
Slc38a4 |
solute carrier family 38, member 4 |
decreases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in decreased expression of SLC38A4 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995
|
|
G |
Slc39a11 |
solute carrier family 39, member 11 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of SLC39A11 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:98,275,958...98,697,042
Ensembl chr10:98,275,960...98,611,295
|
|
G |
Slc46a3 |
solute carrier family 46, member 3 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of SLC46A3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr12:7,140,610...7,157,093
Ensembl chr12:7,140,668...7,157,092
|
|
G |
Slc7a3 |
solute carrier family 7 member 3 |
increases expression |
EXP |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of SLC7A3 mRNA |
CTD |
PMID:19480007 |
|
NCBI chr X:66,210,071...66,216,482
Ensembl chr X:66,210,081...66,215,708
|
|
G |
Slit2 |
slit guidance ligand 2 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in increased expression of SLIT2 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
|
|
G |
Slit3 |
slit guidance ligand 3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of SLIT3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634
|
|
G |
Smyd3 |
SET and MYND domain containing 3 |
decreases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene metabolite results in decreased expression of SMYD3 mRNA |
CTD |
PMID:32553695 |
|
NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
increases expression |
ISO |
9,10-Dimethyl-1,2-benzanthracene results in increased expression of SNAI1 mRNA; 9,10-Dimethyl-1,2-benzanthracene results in increased expression of SNAI1 protein |
CTD |
PMID:29663660 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snrnp70 |
small nuclear ribonucleoprotein U1 subunit 70 |
affects expression |
| |